PV Bulletin

FDA Study Data Technical Conformance Guide Update

FDA updated the Study Data Technical Conformance Guide, affecting submission requirements for clinical trial and post-marketing study data.

Primary source: Food and Drug Administration (FDA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

Sponsors and Marketing Authorization Holders (MAHs) must ensure that clinical trial and post-marketing study data submissions comply with the updated technical specifications outlined in the FDA's latest guidance.

Why it matters

Failure to comply with updated specifications could result in submission rejection or delays in the safety review process, impacting regulatory timelines and organizational responsibilities.

Action needed

Review and update data submission practices to align with the new technical specifications; ensure compliance with FDA-supported data standards.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Technical Guidance
Policy status
revised
Publication date
12 June 2026
Policy change
FDA published an updated version of the Study Data Technical Conformance Guide, providing technical specifications for the submission of study data. This document represents the Agency's current thinking on the technical conformance of study data submissions in electronic format.

Key changes

Updates to technical specifications for study data submissions; refined guidance on conformance with FDA-supported data standards (e.g., CDISC SDTM/ADaM).

Affected workflows

ICSRCountry Compliance

Responsible groups

Clinical Data ManagementPV OperationsRegulatory Affairs

PV impact

Sponsors and MAHs submitting clinical trial or post-marketing study data (e.g., for DSURs or PASS) must ensure their data sets comply with the updated technical specifications. Conformance failures can lead to submission rejection or delays in safety reviews.

View regulator source

Source document details

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 12, 2026

Full briefing

Practical implication

Review and update data submission practices to align with the new technical specifications; ensure compliance with FDA-supported data standards.

FDA published an updated version of the Study Data Technical Conformance Guide, which provides technical specifications for the electronic submission of study data. This change refines requirements regarding compliance with FDA-supported data standards like CDISC SDTM/ADaM. Non-compliance may lead to rejection of submissions or delays in safety reviews.

What changed: Sponsors and Marketing Authorization Holders (MAHs) must ensure that clinical trial and post-marketing study data submissions comply with the updated technical specifications outlined in the FDA's latest guidance.

Why it matters: Failure to comply with updated specifications could result in submission rejection or delays in the safety review process, impacting regulatory timelines and organizational responsibilities.

Practical implication: Review and update data submission practices to align with the new technical specifications; ensure compliance with FDA-supported data standards.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Country Guides#Reporting Requirement#revised#policy-change#firecrawl-policy-agent#Technical Guidance#Food and Drug Administration (FDA)

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward